Pilot and Feasibility Clinical Research Grants in Diabe...

Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21)

Pilot and Feasibility Clinical Research Grants in Diabetes, Endocrine and Metabolic Diseases (R21)

Mary Kay Rosenberg
Grants Management Branch
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Blvd., Room 708
Bethesda, MD 20892
Phone: (301)594-8891
Fax: (301) 480-3504

Announcement Type
New

Update: The following update relating to this announcement has been issued:

* September 17, 2007 - Expiration Date adjusted to accommodate recent changes to standing submission deadlines, per NOT-OD-07-093.

NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants.gov (http://www.grants.gov) using the SF424 Research and Related (R&R) forms and SF424 (R&R) Application Guide. APPLICATIONS MAY NOT BE SUBMITTED IN PAPER FORMAT.

This FOA must be read in conjunction with the application guidelines provided with this announcement in Grants.gov/Apply for Grants (hereafter called Grants.gov/Apply).

A registration process is necessary before submission and applicants are highly encouraged to start the process at least four weeks prior to the grant submission date. See Section IV.

Program Announcement (PA) Number: PA-06-387


For Assistance downloading this or any Grants.gov application package, please contact Grants.gov Customer Support at http://grants.gov/CustomerSupport
Catalog of Federal Domestic Assistance Number(s)
93.847

Key Dates
Release/Posted Date: May 8, 2006
Opening Date: May 8, 2006 (Earliest date an application may be submitted to Grants.gov)
Letters of Intent Receipt Date(s): Not Applicable
NOTE: On time submission requires that applications be successfully submitted to Grants.gov no later than 5:00 p.m. local time (of the applicant institution/organization).
Application Submission Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm
AIDS Application Receipt Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#AIDS
Peer Review Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Council Review Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Earliest Anticipated Start Date(s): Standard dates apply, please see http://grants1.nih.gov/grants/funding/submissionschedule.htm#reviewandaward
Expiration Date: May 2, 2009 (now May 8, 2009 per NOT-OD-07-093)

Due Dates for E.O. 12372
Not Applicable

Additional Overview Content

Executive Summary

* The Pilot and Feasibility Clinical Research Grants Program is designed to support short-term clinical pilot studies and planning activities to help stimulate the translation of promising research developments from the laboratory into clinical practice for diabetes, endocrine and metabolic diseases.
* The Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases invites applications for the exploratory/developmental (R21) grant mechanism in selected areas of opportunity within our mission. The intent of this initiative is to encourage researchers to apply novel technologies, develop new tools, biomarkers and model systems, and test innovative concepts of potential diagnostic and therapeutic relevance to diseases within our mission including diabetes and its complications, obesity, endocrine disorders including osteoporosis, and inborn errors of metabolism including cystic fibrosis. The R21 mechanism is intended to encourage exploratory research projects by providing support at the conceptual stages of these projects.
* Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the quality, duration, and costs of the applications received.
* Project Period and Award Levels: The total project period for an application submitted in response to this funding opportunity may not exceed 2 years. Direct costs are limited to $275,000 over the two years of the R21 award, with no more than $200,000 in direct costs allowed in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period.
* This announcement uses the NIH exploratory/developmental grant (R21) award mechanism.
* Eligible organizations: For-profit or non-profit organizations; Public or private institutions, such as universities, colleges, hospitals, and laboratories; Units of State and local governments; Eligible agencies of the Federal government; Domestic or foreign institutions; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); and Indian/Native American Tribally Designated Organization.
* Eligible Project Directors/Principal Investigators (PD/PIs):Any individuals with the skills, knowledge, and resources necessary to carry out the proposed research.
* Applicants may submit more than one application, provided they are scientifically distinct.
* An R21 is not renewable.